

Caspase-independent programmed cell death triggers Ca_2PO_4 deposition in an *in vitro* model of nephrocalcinosis

Giovanna Priante¹, Federica Quaggio¹, Lisa Giancesello¹, Monica Ceol¹, Rosalba Cristofaro¹, Liliana Terrin¹, Claudio Furlan², Dorella Del Prete¹, Franca Anglani¹.

¹ Kidney Histomorphology and Molecular Biology Laboratory, Clinical Nephrology, Dept. of Medicine - DIMED, University of Padua, Padua, ITALY;

² Center for Laboratory Analyses and Certification Services (CEASC), University of Padua, Padua, ITALY

Running title: Cell death in an *in vitro* model of nephrocalcinosis

Corresponding author:

Dr. Giovanna Priante

Laboratorio di Istomorfologia e Biologia Molecolare del Rene

Dipartimento di Medicina - DIMED, Università di Padova

Via G. Orus 2/B,

35129 Padova (ITALY)

phone: +39 0498212155

fax: +39 0498212992;

e-mail: giovanna.priante@unipd.it

ABSTRACT

Nephrocalcinosis involves the deposition of microscopic crystals in the tubular lumen or interstitium. While the clinical, biochemical and genetic aspects of the diseases causing nephrocalcinosis have been elucidated, little is known about the cellular events in this calcification process. We previously reported a phenomenon involving the spontaneous formation of Ca_2PO_4 nodules in primary papillary renal cells from a patient with medullary nephrocalcinosis harboring a rare *GDNF* gene variant. We also demonstrated that cultivating *GDNF*-silenced HK-2 cells in osteogenic conditions for 15 days triggered Ca_2PO_4 deposits. Given the reportedly close relationship between cell death and pathological calcification, the aim of this study was to investigate whether apoptosis is involved in the calcification of *GDNF*-silenced HK-2 cells under osteogenic conditions. Silenced and control cells were cultured in standard and osteogenic medium for 1, 5 and 15 days, and any Ca_2PO_4 deposition was identified by means of von Kossa staining and ESEM analyses. Based on the results of annexin V and propidium iodide analysis, and TUNEL assay, the silenced cells in the osteogenic medium showed a significant increase in the percentage of cells in the late phase of apoptosis and an increased Ca_2PO_4 deposition at 15 days. The results of qRT-PCR of *BAX* and *BCL2*, and in-cell Western analysis of caspases indicated that the cell death process was independent of caspase-3, -6, -7 and -9 activation, however. Using this model, we provide evidence of caspase-independent cell death triggering the calcification process in *GDNF*-silenced HK-2 cells.

Abbreviations list:

GDNF: glial-cell-derived neurotrophic factor

HK-2: human kidney-2

ESEM: environmental scanning electron microscope

TUNEL: terminal deoxynucleotidyl transferase dUTP nick end labeling

qRT-PCR: quantitative real-time polymerase chain reaction

MSK: medullary sponge kidney

VSMC: vascular smooth muscle cell

ATCC: American type culture collection

shRNA: short hairpin RNA

ICC: immunocytochemistry

RT: room temperature

WT: wild type

ALP: alkaline phosphatase

PI: propidium iodide

FITC: fluorescein isothiocyanate

NCBI: National Center for Biotechnology Information

GAPDH: glyceraldehyde 3-phosphate dehydrogenase

HPRT: hypoxanthine guanine phosphoribosyl transferase

MIQE: minimum information for publication of quantitative real-time PCR experiments

nRQ: normalized relative quantities

INTRODUCTION

Many *in vitro* and *in vivo* studies on the mechanisms underlying calcium nephrolithiasis have provided evidence of a condition frequently associated with nephrocalcinosis, which involving the deposition of microscopic crystals in the tubular lumen (intratubular nephrocalcinosis) or interstitium (interstitial nephrocalcinosis) (1-3). While the clinical, biochemical and genetic aspects of the diseases causing nephrocalcinosis have been thoroughly elucidated, little is known about the specific cellular events involved in this calcification process. The most accredited hypothesis to explain the onset of interstitial nephrocalcinosis is purely physicochemical and related to spontaneous Ca_2PO_4 crystallization in the interstitium due to calcium and phosphate oversaturation in this milieu (4, 5). Exactly how the tubulo-interstitial cells respond to the influx of these potentially precipitating ions is still unknown. We were the first to suggest that nephrocalcinosis might be an osteogenic-like cell-driven process (6, 7), and our previous studies provided the first evidence of human renal cells undergoing calcification under certain circumstances, such as *GDNF* gene down-regulation, in much the same way as in vascular calcification (8). We had the chance to observe spontaneous instances of this phenomenon in primary renal cells derived from a patient with medullary sponge kidney (MSK) and interstitial nephrocalcinosis who carried a *GDNF* gene mutation. We also demonstrated that, when exposed to an osteogenic medium, renal tubular HK-2 cells with a silenced *GDNF* expression were better able to produce Ca_2PO_4 deposits than control cells by shifting the osteonectin/osteopontin ratio in favor of osteonectin. This finding was the first indication of a role for GDNF in the tubular renal cell calcification process (8).

A fundamental question remaining to be answered concerns the cellular mechanisms by means of which *GDNF* down-regulation promotes the calcification process. The assumption explored in the present study was that down-regulated *GDNF* could favor cell death

phenomena, and apoptosis in particular. The importance of cell death in pathological calcification has been well documented (9-12). It has been claimed, for instance, that chondrocyte-derived apoptotic bodies might contribute to the calcification of articular cartilage (10). In advanced carotid atherosclerotic plaques, matrix vesicle-like structures derived from vascular smooth muscle cells (VSMCs) were found to contain high levels of BAX, a pro-apoptotic member of the BCL2 family, indicating that they may be remnants of apoptotic cells (11, 12). Apoptotic VSMC-derived matrix vesicle-like structures can also concentrate and crystallize calcium, triggering calcification (12-15). These findings suggest that calcification may be initiated by apoptotic bodies in cooperation with matrix vesicles. It has long been known that pathological calcification follows necrosis in cardiovascular tissues and in the kidney (16-18). In normal bone formation too, calcification is initiated in matrix vesicles, released from osteoblasts and hypertrophic chondrocytes, and facilitated by apoptotic bodies (19-23).

All these findings led to the idea that cell death could be important in initiating ectopic calcification in renal cells under certain conditions. To test our hypothesis, we used a previously-adopted *in vitro* experimental model of down-regulated *GDNF* in HK-2 cells (8). This enabled us to demonstrate that cell death can trigger the calcification process in renal tubular cells, and that *GDNF* down-regulation strongly facilitates this process. We thus confirmed the role of *GDNF* as an adaptive survival factor, and its alteration appears to have a key role in nephrocalcinosis. We also discovered that, in *GDNF*-silenced cells, death occurs in a programmed but caspase-independent manner.

EXPERIMENTAL

Cell culture

The human renal proximal tubular cell line HK-2 (human kidney-2) was purchased from ATCC (CRL-2190™). HK-2 cells were maintained in a mixture of Ham's F12 and Dulbecco's modified Eagle's growth medium (DMEM/F12; EuroClone, Celbio) supplemented with 10% heat-inactivated fetal bovine serum (HI-FBS), 2 mM L-glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin (EuroClone, Celbio). Cells were grown in a humidified atmosphere of 5% CO₂ and 95% air at 37°C. The cells were seeded at an appropriate cell density for different assays and left to grow to 80% confluence, then cell synchronization was performed routinely by incubating cells in serum-free medium for 24 h prior to each experiment. The cells were exposed to different experimental conditions. The growth medium was replaced every 2 to 3 days.

GDNF knock-down in the HK-2 cell line

Our *in vitro* model of nephrocalcinosis was established by silencing GDNF in HK-2 cells. To obtain stable GDNF-silenced cells, five different shRNAs targeting human GDNF (NM_000514) purchased from Sigma-Aldrich were used. Each plasmid was separately transfected, and a sixth transfection was performed with all five plasmids concurrently, according to the manufacturer's protocol (Mirus Madison). Cells (1.5×10^5 cells per well) were transfected with 3 µg of plasmid DNA using the TransIT-LT1 transfection reagent (Mirus, Madison). Negative control cells were transfected with an empty pRS plasmid vector without shRNA (TR20003), using the same amount of TransIT-LT1 transfection reagent. Transfected cells underwent several weeks of selection with 0.75 µg/ml puromycin (Sigma-Aldrich), and clones with different resistances were obtained from each 29mer shRNA targeting GDNF mRNA, as well as from the corresponding negative controls. GDNF mRNA

expression was assessed in all the clones using qRT-PCR, as described below. GDNF silencing was also assessed at protein level using immunocytochemistry (ICC) with a polyclonal GDNF antibody (Santa Cruz Biotechnology). Briefly, ICC staining was performed on HK-2 cells fixed with cold methanol for 5 minutes at RT. The cells were then treated with 3% H₂O₂ in PBS (pH 7.4) for 15 minutes at RT to remove endogenous peroxidase activity, and incubated with 2% normal goat serum (Sigma-Aldrich) for 30 minutes at RT to prevent nonspecific antibody binding. Samples were incubated with a rabbit antibody targeting GDNF (Santa Cruz Biotechnology) diluted 1:200 in PBS at 4°C overnight. Samples were then rinsed with PBS and treated with a DakoCytomation EnVision+System-HRP Labeled Polymer anti-rabbit antibody (DAKO Corporation) in a humidified chamber at RT for 30 minutes. Signals were visualized using the chromogen 3,3-diaminobenzidine-tetrachloride (DAB, DAKO), and the cells were counterstained with hematoxylin. The specificity of the immunolabeling was confirmed in treated cells without the primary antibody. Slides were analyzed by Diaplan light microscope (Leitz). Images were acquired using a Micropublisher 5.0 RTV camera (Q Imaging). GDNF protein quantification was performed by morphometric analysis.

Among the shRNA sequences, the one exhibiting the greatest degree of silencing was chosen for all subsequent experiments (shRNA 4E).

Osteogenic culture of HK-2 cells

Wild-type (WT), negative control (cells transfected with an empty vector), and GDNF-silenced HK-2 (shRNA 4E) cells were cultured in 6-well tissue culture plates (Falcon™ Polystyrene Microplates, Thermo Scientific) at a density of 4.5×10^4 cells per well in commercially-available osteogenic medium (NH OsteoDiff medium, Miltenyi Biotec) for 1, 5 or 15 days. Control conditions were established by culturing cells in DMEM/F12 medium.

The osteogenic and the DMEM/F12 medium were both replaced every 2 to 3 days for up to 15 days. The osteogenic stimulation experiments were run twice.

Detecting and quantifying calcification

Alkaline phosphatase staining

Histochemical staining for alkaline phosphatase (ALP), an enzyme involved in bone matrix mineralization and an early marker of committed osteogenic cells, was performed with a commercially-available kit (SIGMA FAST BCIP/NBT, Sigma-Aldrich). Cells were seeded in chamber slides (4×10^3 cells/well; Nunc Lab-Tek Chamber Slide system; 8 wells on Permanox; Thermo Scientific). After incubation in standard or osteogenic media for 1, 5 or 15 days, cells were washed twice with PBS and then fixed with pre-chilled methanol for 10 minutes at RT. After the methanol was removed, cells were washed with deionized H₂O, treated with SIGMA FAST BCIP/NBT substrate on the cell culture chamber slides, and agitated slowly on a plate shaker for 10 minutes at RT. The substrate solution was aspirated, and the slides were washed twice with deionized H₂O. Slides were mounted in a glycerol and water solution, and analyzed under a Leica DMIL LED phase-contrast inverted microscope (Leica Microsystems). Images were acquired using a LEICA ICC50W camera. Alkaline phosphatase positive signals in the cells were detected as an intense granular blue/purple stain and were quantified by morphometric analysis.

Von Kossa staining

Von Kossa staining was used to detect calcium crystal deposition. Cells were seeded in an 8-well chamber slide system (4×10^3 cell/well), incubated in standard (DMEM/F12, 10% HI-FBS) or osteogenic media for 1, 5 or 15 days, and then washed twice with PBS. They were

then fixed in PBS-formalin for 10 minutes. After washing twice with PBS and once with water, a 2% silver nitrate solution was added. The slides were exposed to UV light for 30 minutes and, after rinsing once again with water, sodium thiosulfate (5%) was added for 3 minutes. The slides were again rinsed in water, then hematoxylin was added for 5 minutes to counterstain the nuclei. After rinsing in water for the last time, the slides were mounted in a glycerol and water solution and then visualized using a Diaplan light microscope (Leitz).

To quantify the calcium deposition, images were acquired using a Micropublisher 5.0 RTV camera (Q Imaging), and morphometric analysis of the von Kossa staining was performed.

Environmental scanning electron microscopy (ESEM) analysis

After seeding in 8-well slides (4×10^3 cells/well) and treatment, cells were washed twice with PBS and fixed in methanol for 10 minutes. To assess the chemical composition of the cell nodules, ESEM analysis with X-ray fluorescence, coupled with energy-dispersive spectroscopy (XRF-EDS), was performed directly on the cells grown on the plastic slides using an ELEMENT instrument (EDAX). This method enables the identification of inorganic compounds within a biological matrix typically comprising carbon, oxygen, and hydrogen. The spectra gathered in the X-ray fluorescence show the peaks of all the elements involved, so a semiquantitative measure of the composition of the inclusions can be obtained by analyzing the net intensities calculated by the peak integral with background line subtraction.

Detecting and quantifying cell death

Cell growth and viability assessment

Cells were plated at 10×10^3 cells/well in 24-well tissue culture plates (Falcon) and grown to 50% confluence in culture medium, then the medium was switched to 1% FCS 24 h before

the experiments to induce quiescence. A standard (DMEM/F12, 10% HI-FBS) or osteogenic (NH OsteoDiff medium, Miltenyi Biotec) medium was added to the cells and changed every two days. Proliferation was assessed at different times (on days 0, 1, 2, 3, 4, 7, and 8), by means of cell counts and colorimetric assays (24, 25). Briefly, cells were fixed with methanol for 10 minutes, then stained with 1% methyl blue in 0.01 M borate buffer (pH 8.5) for 30 minutes. After repeated washing, the unbound staining solution was eluted with a 1:1 mixture of ethanol and 0.1 N HCl, and read at an absorbance of 650 nm. Methyl blue only stains cells attached to the substrate before fixation (i.e. living cells), and thus quantifies their proliferation and viability.

Simultaneous annexin V-FITC and propidium iodide staining

Phosphatidylserine externalization was assessed at different time points by measuring annexin V and propidium iodide (PI), using a kit from Affymetrix-eBioscience according to the manufacturer's instructions. Briefly, after washing with PBS, the cells were detached using trypsin and resuspended at a density of $200-500 \times 10^3$ cells/ml in 100 μ l annexin binding buffer (10 mM HEPES, pH 7.4; 140 mM NaCl, and 2.5 mM CaCl_2) containing 5 μ l of annexin V-FITC. This mixture was incubated for 10 minutes at RT in the dark, then the cells were washed with binding buffer and resuspended in the same buffer containing PI. A minimum of 1×10^4 cells were then analyzed, and the apoptotic stages were examined by flow cytometry using a CytoFLEX cytometer (Beckman Coulter). AnnexinV-positive/PI-negative and annexinV-positive/PI-positive cells were considered in the early and late apoptotic phases, respectively. AnnexinV-negative/PI-positive cells were considered necrotic. All cell populations were counted together and defined as the total dead cell population. Staurosporine (1.0 μ M)-treated cells were used as a positive control.

Detecting in situ cell death with the TUNEL assay

DNA fragmentation was assessed using the terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling (TUNEL) assay (TUNEL In Situ Cell Death Detection Kit, Roche). Cells were seeded on chamber slides, and cultured for 1, 5 or 15 days in normal and osteogenic media (4×10^3 cells/well). Cell cultures were fixed with 4% formaldehyde in PBS for 10 minutes at RT, and permeabilized with 0.1% (vol/vol) Triton X-100 in aqueous 0.1% (wt/vol) sodium citrate for 2 minutes on ice. Next, the cells were incubated for 1 h at 37°C with a TUNEL reaction mixture comprising a nucleotide mixture in reaction buffer and terminal deoxynucleotidyl transferase (TdT). The slides were washed three times with PBS, mounted in a glycerol and water solution, examined using a DMI600CS-TCS SP8 fluorescence microscope (Leica Microsystems), and analyzed with LAS AF software (Leica Microsystems). Images were acquired using a DFC365FX camera (Leica Microsystems) and morphometric labeling assessment was done. Cells treated with 20.0 U/ μ l DNase I for 20 minutes were used as a positive control.

In-Cell Western

Caspase activation and Runx2 protein expression was assessed using In-Cell Western analysis as described elsewhere (26). Cells were seeded in a 96-well plate (2×10^3 cells per well) and cultured in standard or osteogenic media for 1, 5 or 15 days. At the end of the treatment, cells were immediately fixed with cold methanol for 10 minutes at RT, then washed 5 times with 0.1% Triton X-100 in PBS. The samples were blocked in a solution of 5% milk in PBS containing 0.1% Triton X-100 for 40 minutes at RT with moderate shaking followed by incubation with specific primary antibodies (Table 1) overnight at 4°C in a humidified chamber. β -tubulin served as an internal control. The plates were washed five

times with 0.1% Triton X-100 in PBS and gently agitated for 5 minutes at RT. Next, secondary antibody (IRDye 800CW donkey anti-Rabbit, 1:800, from LI-COR, Biotechnology, Lincoln, NE, USA) was added to each well and incubated in the dark for 60 minutes at RT with gentle shaking. Finally, the plates were scanned at 800 nm and intensity of the labelled proteins was measured using the Odyssey Infrared Imaging System (LI-COR). Each experiment was performed in duplicate at least. Negative controls were obtained by omitting the primary antibody during the incubation steps, and background values were obtained by omitting primary and secondary antibodies. The data are shown as the average \pm SD. Staurosporine (1.0 μ M)-treated cells were used as a positive control.

Quantitative real-time PCR

Total RNA was extracted from cell cultures at 1, 5 or 15 days using the RNeasy Mini Kit (Qiagen Limburg, NL) according to the manufacturer's instructions, and following the spin column protocol. RNA quantity and quality were assessed by spectrophotometric analysis using a NanoDrop ND-1000 (Thermo Fischer Scientific Waltham, MA, USA), and by capillary electrophoresis using an Agilent 2100 Bioanalyzer (Agilent Technologies Santa Clara, CA, USA). RNA samples with an A260/A280 ratio between 1.8-2 and an RNA integrity number (RIN) of at least 9 were used for qRT-PCR. A total of 100 ng of total RNA was reverse-transcribed in a final volume of 20 μ l containing 5 mM MgCl₂, 1 mM dNTPs, 2.5 μ M random hexamers (Applied Biosystems), 1 U/ μ l RNase inhibitor (Applied Biosystems), and 2.5 U/ μ l MuLV reverse transcriptase (Thermo Fischer Scientific) in a buffer comprising 50 mM KCl and 10 mM Tris-HCl (pH 8.3). Reactions were performed on a 2720 Thermal Cycler (Thermo Fisher Scientific) using the following thermal profile: RT for 10 minutes, 42°C for 30 minutes, 65°C for 5 minutes, and 4°C for 5 minutes. The primers used are listed in Table 2. Primer pairs for the region of interest were designed using Primer3 software ver.

4.0 (<http://primer3.ut.ee>), adopting stringent parameters to ensure successful amplification and a convenient experimental design. The NCBI Primer-BLAST program was used for in silico specificity analysis (www.ncbi.nlm.nih.gov/tools/primer-blast/index.cgi), after which each primer pair was validated. Microchip electrophoresis on an Agilent 2100 Bioanalyzer, Sanger sequencing and melting curve analyses were used to measure the specificity of the PCR reactions. Amplification curves were established for all the primers and resulted in an 85% efficiency, at least. qRT-PCR was performed using an iCycler Thermal Cycler (Bio-Rad Hercules, CA, USA) and SYBR Green I technology with iQTM SYBR Green Master Mix (Bio-Rad) in a final volume of 20 μ l final volume containing 1 μ l of reverse-transcribed cDNA template. An appropriate primer concentration (0.3 μ M) was used, and the annealing temperatures are listed in Table 1. Data analysis was performed using the $\Delta\Delta$ Ct method, normalizing the data to two different housekeeping genes (*GAPDH* and *HPRT1*) according to the MIQE guidelines (27). The normalized relative quantification (nRQ) was calculated as $2^{-\Delta\Delta C_t}$. A melting curve analysis was performed to identify any nonspecific amplification products. The results were obtained from two separate experiments performed in triplicate.

Morphometric analysis

Morphometric analysis was performed by Image-Pro Plus software (Media Cybernetics). For each experimental sample, a maximum of 15 images at 200X or 400X magnification was analyzed. Signals were acquired for all the images with the same brightness and contrast characteristics from three different slides and the quantity was expressed as the percentage of the mean area covered by pixels (28, 29).

Statistical analysis

Data are presented as means \pm SDs. Multiple group means were compared using ANOVA with a between-within design and Bonferroni's correction. Data from the morphometric analysis were examined using a non-parametric test (the Mann-Whitney U test), and statistical significance was established with the Primer software (McGraw-Hill). A *p* value of less than 0.05 was considered statistically significant.

RESULTS

An osteogenic-like process occurred in the calcification of *GDNF*-silenced HK-2 cells

In *GDNF*-silenced HK-2 cells, gene knock-down resulted in an approximately 70% reduction in *GDNF* transcript and 60% in protein levels (Figure 1). There was a multilayered growth in both the control and the silenced cells cultured in osteogenic conditions, with cells retracting from some areas and grouping into multicellular aggregates or nodules. The silenced cells also exhibited many more nodules with dense deposits than the control cells, and this became increasingly evident over time (Figure 2).

Notably, this distinct “hill and valley” morphology developed in parallel with the deposition of calcium aggregates (as revealed by von Kossa staining), which was detectable already after 5 days of culture, and increased substantially over 15 days (Figure 3). When the von Kossa staining was measured using morphometric analysis, there was significantly more calcium deposition in the silenced than in the control cells at 5 ($p < 0.05$) and 15 days ($p < 0.005$ vs WT; $p < 0.01$ vs Negative control) (Figure 3 B). No calcium deposition was seen in the control or silenced cells cultured under standard conditions (Figure 3 A). ESEM analysis revealed that the granular concretions ranged from 1.0 to 40 μm in diameter, and contained an abundance of calcium and phosphate (Figure 4). The concomitant presence of calcium and phosphate suggests Ca_2PO_4 precipitation in the nodules. Much smaller amounts of these aggregates were also seen in the WT and control cells cultured in osteogenic conditions (Figure 4 B).

The gene expression of osteoblastic markers such as Runx2 (an early osteogenic programming gene) and osteopontin and osteonectin (later osteogenic programming genes), was measured over the course of osteogenic induction to see if Ca_2PO_4 deposition was related to an osteogenic-like process. We detected a significant increase of Runx2 expression at days 1 and 5 compared to day 15 (Figure 5 A). However, no difference between *GDNF*-silenced

HK-2 cells and control cells was found. A difference between control and silenced cells was instead demonstrated by evaluating Runx2 expression at protein level by In-Cell Western. In fact, Runx2 was significantly higher in silenced cells than in control cells at 5 days ($p < 0.05$ vs Negative Control $p < 0.005$ vs WT).

Figure 5 B shows that the osteonectin/osteopontin ratio was significantly higher in the *GDNF*-silenced HK-2 cells than in the control cells. The highest osteonectin/osteopontin ratio was recorded after 5 days ($p < 0.005$ shRNA 4E vs Negative Control; $p < 0.01$ shRNA 4E vs WT).

On cytochemical examination of ALP activity, *GDNF*-silenced cells showed a significant higher positive signal than control cells after 15 days of treatment with osteogenic medium ($p < 0.005$ vs Negative Control and WT) (Figure 5 C). Positive signals were detected predominantly around the nodules and were observed also in some of the control cells.

Massive cell death occurred in the calcified nodules of *GDNF*-silenced HK-2 cells

Cell proliferation was analyzed first. Cells were monitored for 1 to 8 days, and control cells exhibited a similar growth in the standard and osteogenic media, with a gradual time-dependent increase in their growth (Figure 6). At each time point on the growth curve, *GDNF*-silenced HK-2 cells exhibited significantly less proliferation than control cells ($p < 0.005$), pointing to the role of GDNF as a survival factor for renal tubular cells too. The silenced cells in osteogenic medium did start to grow after 4 to 7 days of culture, however, albeit more slowly than the control cells ($p < 0.005$) (Figure 6).

Then the cell death process was examined and quantified by means of a simultaneous staining with annexin V-FITC and PI, which enabled us to discriminate between apoptotic and non-

apoptotic cell death. Under osteogenic conditions, there was an overall increase in the cell death rate at 15 days compared with the rate at 5 days, in both control and silenced cells (Figure 7 A), but the difference was greater in the latter ($p < 0.05$). Phosphatidylserine externalization usually occurs in the inner leaflet of the plasma membrane, and is one of the earliest signs of apoptosis, preceding DNA fragmentation and membrane blebbing. After 5 days in osteogenic medium, there was a predominant population in the early apoptotic phase (annexinV-positive/PI-negative), which was significantly greater in the silenced than in the control cells ($p < 0.05$). (Figure 7 B). After 15 days in osteogenic medium, there were two predominant types of dead cell population, one only PI-positive (necrotic cells), the other was annexinV-positive and PI-positive (cells in late apoptosis). This latter population was significantly more evident in the silenced than in the control cells ($p < 0.05$) (Figure 7 B). The various phases of the process appeared to have been completed within the time window considered, indicating a transition from early to advanced or late apoptosis. In standard culture conditions, the dead cells were more numerous among the silenced cells, but they were mainly in the early phase of apoptosis (data not shown). These results again point to GDNF acting as a survival factor for the renal tubular cells.

One of the most common hallmarks of apoptosis is DNA fragmentation, so DNA content in the *GDNF*-silenced HK-2 cells was analyzed by TUNEL assay. While no positive staining was observed at 5 days, several nodules had positively stained nuclei in the silenced cells after 15 days of culturing, meaning that these cells were probably apoptotic (Figure 8). There were few positive nodules in the control cells but the signal was less intense, and the number of late apoptotic cells was significantly lower than in the silenced cells ($p < 0.05$), while there were more necrotic cells (Figure 7 B). No staining was apparent in any areas/cells around the nodules, or in cells cultured in standard conditions (data not shown). Taken together, these

findings indicate that the presence of apoptotic bodies in the nodules was associated with the calcification process.

The death process in *GDNF*-silenced HK-2 cells is caspase-independent

Activation of the apoptotic process was examined by measuring *BCL2* (anti-apoptotic) and *BAX* (pro-apoptotic) gene expression using qRT-PCR. Silenced cells cultured in the osteogenic medium showed a significantly higher *BCL2* expression at 1 ($p < 0.005$) and 5 ($p < 0.05$) days than the control cells, while *BAX* expression increased over time but no more than in the control cells (Figure 9).

The onset of apoptosis is characterized by caspase-3, -6, -7 and -9 activation in the cytosol. In-Cell Western analysis was performed on the control and *GDNF*-silenced cells grown in osteogenic medium to detect any presence of activated caspases. The levels of cleaved caspase-9 (an initiator caspase), and cleaved caspase-3, -6 and -7 (effector caspases) were measured, and so were those of cleaved nuclear protein poly- (ADP-ribose) polymerase (PARP), which is a caspase substrate. Silenced cells exhibited significantly lower caspase and PARP levels than control cells at both 5 and 15 days (Figure 10 A).

DISCUSSION

We previously reported that an unexpected calcification process spontaneously occurred in primary papillary cells obtained from the kidney biopsy of a patient with MSK and interstitial nephrocalcinosis who harbors a *GDNF* gene mutation (8). We also demonstrated that culturing *GDNF*-silenced HK-2 cells in osteogenic medium induced Ca_2PO_4 deposition and the expression of osteoblast differentiation markers (8). Further investigations were warranted, however, to see whether *GDNF* down-regulation directly causes or contributes to the osteogenic-like calcification process seen in primary renal and HK-2 cells.

This study sought to ascertain whether down-regulating *GDNF* could lead to cell death and thus trigger a process of nephrocalcinosis under certain conditions. *GDNF* is known to have survival-supporting properties in neurons (30). In the kidney, it was found to act in an autocrine manner, supporting podocyte survival (31). The important protective role of *GDNF* in the apoptotic process is supported by the literature regarding not only the kidney (31-33), but also the bowel. In Crohn's disease, for instance, *GDNF* protects the enteric glial cells of the intestinal mucosa against apoptosis, thus preserving its integrity and function (34). *GDNF* down-regulation might therefore conceivably trigger calcification by favoring cell death.

A previously-adopted *in vitro* experimental model of *GDNF* down-regulation in HK-2 cells was used here to elucidate the mechanisms underlying the calcification process in renal cells (8). *GDNF* expression levels were monitored at various times during osteogenic induction and under standard conditions, and the results indicated that *GDNF* expression was always significantly lower in silenced than in control cells (data not shown).

The occurrence of an osteogenic-like process in our model, which began after 5 days of culture, was confirmed by the early *Runx2* upregulation and by the increase in the osteonectin/osteopontin expression ratio. This observation is in keeping with findings

suggesting Runx2 triggers the expression of major bone matrix genes during early stages of osteoblasts differentiation, and its overexpression stops in the later stage and is not essential for maintenance of these gene expressions in mature osteoblasts (35, 36). Osteonectin is known to promote the formation of mineral deposits (37), whereas osteopontin is considered a powerful inhibitor of crystal formation (38-40). Our results indicate that the balance between these latter pro- and anti-osteogenic factors in the shRNA 4E cells favored an osteogenic process. The quantification of ALP activity, a later osteoblast differentiation marker (41), further confirmed the osteoblastic-like phenotype of silenced cells cultured in osteogenic medium. Thus, the pattern of expression of both Runx2, and osteonectin/osteopontin, as well as ALP confirm that an active osteogenic-like process occurred in the *GDNF*-silenced HK-2 cells in osteogenic culture, inducing calcification that was detectable already after 5 days of culture, and increased considerably over 15 days. This calcification was localized exclusively in the nodules and/or cell aggregates. These results further support our hypothesis of a procalcifying stimulus of *GDNF* downregulation (8).

Having ascertained that *GDNF* massively favored the Ca_2PO_4 deposition process in our in vitro model of nephrocalcinosis, we investigated whether cell death had occurred under the same conditions. The slow proliferation of silenced cells in the standard and osteogenic media appeared to support the primary hypothesis of this work, i.e. that *GDNF* down-regulation may be related to cell death phenomena, and potentially to apoptosis. Different methods were used to investigate this issue, which shed light on how the cell death process occurred.

Both late apoptotic and necrotic cells were amply represented in the control and silenced cells cultured in osteogenic medium for 15 days. In the *GDNF*-silenced cell population, the apoptotic cells were found in abundance and exclusively in the nodules where calcium and phosphate precipitated, suggesting that they served as nuclei for calcification.

The increase in annexin V-positive cells at 15 days, associated with PI-positive staining, might be due not only to the phosphatidylserine externalization associated with late phases of apoptosis, but also to the loss of membrane integrity characteristic of secondary necrosis (i.e. necrosis after apoptosis). In fact, cells with impaired membranes are also labeled with annexin V-FITC, which enters the cells and stains the internal surface of the plasma membrane, where phosphatidylserine is normally found. Some Authors therefore suggest that concurrently assessing both probes only enables us to distinguish between early-stage apoptotic cells (annexinV-positive/PI-negative) and necrotic cells (annexinV-positive/PI-positive, and annexinV-negative/PI-positive) (42, 43). In other words, the annexinV-positive/ PI-positive cells may be in a later stage of apoptosis and/or undergoing secondary necrosis.

Necrosis causes DNA cleavage too, though such cleavage is not characteristically internucleosomal. TUNEL assay may not distinguish the internucleosomal DNA cleavage of apoptosis from the DNA cleavage of necrosis (44, 45). The present results nonetheless confirm that many cells within the nodule underwent cell death after between 5 and 15 days of osteogenic culture. They also suggest that both necrotic and apoptotic cells may serve as nuclei for calcification. In fact, the osteogenic culture of *GDNF*-silenced cells induced cell death in a time-dependent manner, and the apoptotic process was completed by day 15, when the quantity of calcified nodules was at its highest.

During the apoptotic process, mitochondrial outer membrane permeabilization is regulated by various proteins, such as those encoded by the mammalian *BCL2* family of genes (46, 47), which can directly promote or inhibit apoptosis. *BCL2* protein inhibits the formation of a pore formed by *BAX*, which promotes apoptosis by competing with *BCL2*. *BAX* and *BCL2* were therefore selected as pro- and anti-apoptotic markers, respectively, for our gene expression study. While a temporal increase in *BAX* was observed under osteogenic conditions (with no difference between the silenced and control cells), there was a surprisingly and significantly

higher level of *BCL2* in the GDNF-silenced cells after 1 and 5 days of culture. *BCL2* is an anti-apoptotic protein that regulates apoptosis at mitochondrial level by maintaining the integrity of the mitochondrial membrane and blocking the release of apoptosis factors such as cytochrome C from the mitochondria to the cytoplasm, thereby preventing the activation of the caspase cascade. Consistently, we found a lower quantity of cleaved caspases in the *GDNF*-silenced cells than in the control cells. The high *BCL2* expression in the former cells probably inhibits caspase cleavage and subsequent activation.

These findings in the *GDNF*-silenced cells appear to contrast with the flow cytometry and TUNEL results, which confirmed a massive presence of cells in the late phase of apoptosis. Though they were undergoing apoptosis, the control cells cultured in osteogenic conditions did not display *BCL2* up-regulation or caspase down-regulation, indicating that the apoptotic process underway was caspase-dependent. It is worth adding that calcification was less pronounced in the control cells that underwent a quantitatively and qualitatively different cell death process: a caspase-independent cell death seemed to be peculiar to GDNF-silenced cell calcification. These cells also underwent a process of necrosis. Collectively, these data seem to indicate that - instead of preventing cell death as such - inhibiting postmitochondrial protease activation causes a shift from the apoptotic to another mode of programmed cell death.

In an in vivo model of vascular calcification, cell death proved to be caspase-dependent apoptosis (48). During osteoblastic differentiation of human mesenchymal cells in vitro, both necrotic and apoptotic cells were found to serve as nuclei for calcification (49). In our in vitro model of renal calcification, the cell death process was caspase-independent. Several types of programmed cell death in which caspase activation plays no part (50, 51) have been described so far, including: those that involve no DNA fragmentation, such as autophagy-related cell death (52) and paraptosis (53, 54); and those that lead to a regulated form of necrosis, or

necroptosis (55,56), which is considered an adaptive response to ensure the elimination of damaged cells and protect the well-being of the organism as a whole. Necroptosis is activated in a programmed fashion similar to apoptosis, but morphologically exhibits the hallmarks of necrosis. The programmed cell death seen in our model could be classified as necroptosis, as its characteristics were intermediate between apoptosis and necrosis. The cell death seen in our model was clearly caspase-independent, however. Several necroptotic pathways have recently been discovered in renal cells, depending on the initial stimulus, such as calcium crystals (57), cadmium (58), and TNF-alpha (59), or on the type of acute kidney injury (60-62).

Our evidence of the effect of *GDNF* silencing on cell death is consistent with reports from other authors (63, 64), who found no mitochondrial pathway activation in GDNF-deprived sympathetic neurons. Cytochrome *c* was not released from the mitochondria into the cytosol; and BAX and caspases-9 and -3 were not involved in the cell death process. Many cells in which the main mitochondrial death pathway is genetically or pharmacologically disabled can still die via an alternative pathway, which is often caspase-independent (53, 64-68).

The undeniable complexity of the mechanisms involved in cell death has shown that, under certain conditions, markers of apoptosis and necrosis may be found simultaneously, indicating that more than one cell death mechanism can be activated at the same time (69). While there may be signs of different cell death pathways being involved, the fastest and most effective pathway is often predominant (70). In support of our data, studies focusing on the process of osteoblast maturation (a typical osteogenic process) have provided no direct evidence of the activation of caspase-dependent apoptotic processes accompanying osteogenesis (71-73).

In conclusion, GDNF was confirmed as an adaptive survival factor, and its alteration appears to have a key role in nephrocalcinosis. The findings emerging from the present study indicate

that *GDNF* down-regulation can trigger apoptosis in human renal tubular cells and, under certain environmental conditions (e.g. in an osteogenic medium), this can strongly facilitate calcium phosphate deposition. Our results also suggest, however, that this apoptotic process is caspase-independent. Further studies are needed to better define the necroptosis signaling underlying the observed programmed cell death phenomenon.

We are tempted to speculate that, if cell death is an important event in the pathogenesis of renal ectopic calcification, any damage that shifts the balance between cell survival and cell death towards the latter could lead (in conjunction with a particular renal milieu) to the phenomenon of interstitial nephrocalcinosis.

It has long been known that ectopic calcification follows necrosis. In the kidney, cortical nephrocalcinosis (a rare condition usually resulting from severe destructive disease in the cortex) has been attributed to the presence of necrotic tubular cells (18). To our knowledge, no attention has been paid as yet to the role of cell death in the more common interstitial nephrocalcinosis.

CLINICAL PERSPECTIVES

We know that ectopic calcification may follow necrosis. In the kidney, cortical nephrocalcinosis (a rare condition usually resulting from severe destructive disease in the cortex) has been attributed to the presence of necrotic tubular cells. To our knowledge, no attention has been paid as yet to the role of cell death in the more common interstitial nephrocalcinosis. In this study, we demonstrated that programmed cell death played an important part in the renal cell calcification process in an *in vitro* model of nephrocalcinosis. We speculate that, if cell death is an important event in the pathogenesis of renal calcification, any damage that shifts the balance between cell survival and cell death towards the latter

could lead (in conjunction with a particular renal milieu) to the phenomenon of interstitial nephrocalcinosis. The discovery of alternative, caspase-independent cell death pathways demands the search for new strategies - not only for treating disorders such as cancer or ischemic and degenerative diseases, but also for nephrocalcinosis and/or nephrolithiasis.

ACKNOWLEDGMENTS

We would like to thank Valentina Masola of the Department of Biomedical Science for her technical assistance with the *GDNF* gene silencing, and Claudia Maria Radu of the Department of Medicine - DIMED for helping us to establish the technical conditions for flow cytometry.

DECLARATIONS OF INTEREST

The authors have no conflicts of interest to disclose.

FUNDING INFORMATION

This study was supported by a grant (CPDA085494) from the University of Padua.

AUTHOR CONTRIBUTION STATEMENT

GP planned and conducted the experiments, analyzed the data, and wrote the manuscript. FQ, MC, LG, RC and LT conducted the experiments and analyzed the data. CF performed the ESEM analyses. DDP analyzed the data and revised the manuscript. FA coordinated and planned the experiments and wrote the manuscript.

REFERENCES

1. Sayer JA, Carr G, Simmons NL. Nephrocalcinosis: molecular insights into calcium precipitation within the kidney. *Clin Sci (Lond)*. 2004;106: 549–61
2. Vervaeet BA, Verhulst A, D'Haese PC, De Broe ME. Nephrocalcinosis: new insights into mechanisms and consequences. *Nephrol Dial Transplant Rev*. 2009;24: 2030–5.
3. Gambaro G, Trinchieri A. Recent advances in managing and understanding nephrolithiasis/nephrocalcinosis. *F1000Res*. 2016;5:1-8.
4. Bushinsky DA. Nephrolithiasis: site of the initial solid phase. *J Clin Invest*. 2003;111: 602–5.
5. Khan SR. Nephrocalcinosis in animal models with and without stones. *Urol Res*. 2010;38(6):429-38
6. Gambaro G, D'Angelo A, Fabris A, Tosetto E, Anglani F, Lupo A. Crystals, Randall's plaques and renal stones: do bone and atherosclerosis teach us something? *J Nephrol*. 2004;17: 774–7
7. Torregrossa R, Anglani F, Fabris A, Gozzini A, Tanini A, Del Prete D, *et al*. Identification of GDNF gene sequence variations in patients with medullary sponge kidney disease. *Clin J Am Soc Nephrol*. 2010;5(7):1205-10.
8. Mezzabotta F, Cristofaro R, Ceol M, Del Prete D, Priante G, Familiari A, *et al*. Spontaneous calcification process in primary renal cells from a medullary sponge kidney patient harbouring a GDNF mutation. *J. Cell. Mol. Med*. 2015;19: 889-902.
9. Kirsch T. Determinants of pathological mineralization. *Curr Opin Rheumatol*. 2006;18: 174–180.
10. Hashimoto S, Ochs RL, Rosen F, Quach J, McCabe G, Solan J, *et al*. Chondrocyte-derived apoptotic bodies and calcification of articular cartilage. *Proc Natl Acad Sci USA*. 1998;95: 3094–3099.

11. Kockx MM, De Meyer GR, Muhring J, Jacob W, Bult H, Herman AG. Apoptosis and related proteins in different stages of human atherosclerotic plaques. *Circulation*. 1998;97: 2307–2315.
12. Proudfoot D, Skepper JN, Hegyi L, Bennett MR, Shanahan CM, Weissberg PL. Apoptosis regulates human vascular calcification *in vitro*: evidence for initiation of vascular calcification by apoptotic bodies. *Circ Res*. 2000;87: 1055–1062.
13. Johnson RC, Leopold JA, Loscalzo J. Vascular calcification: pathobiological mechanisms and clinical implication. *Circ Res*. 2006;99:1044-1059.
14. Rong S, Zhao X, Jin X, Zhang Z, Chen L, Zhu Y, *et al*. Vascular calcification in chronic kidney disease is induced by bone morphogenetic protein-2 via a mechanism involving the Wnt/ β -catenin pathway. *Cell Physiol Biochem*. 2014;34(6):2049-60.
15. Leopold JA. Vascular calcification: Mechanisms of vascular smooth muscle cell calcification. *Trends Cardiovasc Med*. 2015;25(4):267-74.
16. Cliff WJ. The aortic tunica media in aging rats. *Exp Mol Pathol*. 1970;13:172–189. 15.
17. Klotz O. Studies upon calcareous degeneration: I. The process of pathological calcification. *J Exp Med*. 1905;7: 633–674.
18. Rockley GJ. A case of renal cortical necrosis with dystrophic calcification demonstrated at the Postgraduate Medical School of London. *Br Med. J* 1965;2: 633–636
19. Anderson HC, Garimella R, Tague SE. The role of matrix vesicles in growth plate development and biomineralization. *Front Biosci*. 2005;10: 822–837.
20. Drabek K, van de Peppel J, Eijken M, van Leeuwen JP. GPM6B regulates osteoblast function and induction of mineralization by controlling cytoskeleton and matrix vesicle release. *J Bone Miner Res*. 2011;26: 2045–2051.

21. Boskey AL. Biomineralization: conflicts, challenges, and opportunities. *J Cell Biochem Suppl.* 1998;30-31: 83–91.
22. Wuthier RE, Lipscomb GF. Matrix vesicles: structure, composition, formation and function in calcification. *Front Biosci.* 2012;17: 2812–2902.
23. Kirsch T, Wang W, Pfander D. Functional differences between growth plate apoptotic bodies and matrix vesicles. *J Bone Miner Res.* 2003;18: 1872–1881.
24. Oliver MH, Harrison NK, Bishop JE, Cole PJ, Laurent GJ. A rapid and convenient assay for counting cells cultured in microwell plates: application for assessment of growth factors. *J Cell Sci.* 1989;92(Pt 3):513-518.
25. Musacchio E, Priante G, Budakovic A, Baggio B. Effects of unsaturated free fatty acids on adhesion and on gene expression of extracellular matrix macromolecules in human osteoblastlike cell cultures. *Connect Tissue Res.* 2007;48(1):34-38.
26. Giancesello L, Priante G, Ceol M, Radu CM, Saleem MA, Simioni P, Terrin L, Anglani F, Del Prete D. Albumin uptake in human podocytes: a possible role for the cubilin-annexin (CUBAM) complex. *Sci Rep.* 2017;7(1):13705.
27. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, *et al.* The MIQE guidelines: minimum information for publication of quantitative Real-Time PCR experiments. *Clin Chem.* 2009;55(4): 611-622.
28. Del Prete D, Ceol M, Anglani F, Vianello D, Tiralongo E, Valente M, *et al.* Early activation of fibrogenesis in transplanted kidneys: A study on serial renal biopsies. *Experimental and Molecular Pathology.* 2009;87:141–145.
29. Ceol M, Tiralongo E, Baelde HJ, Vianello D, Betto G, Marangelli A, *et al.* Involvement of the Tubular ClC-Type Exchanger ClC-5 in Glomeruli of Human Proteinuric Nephropathies. *PLoS One.* 2012;7(9): e45605.

30. Tovar-Y-Romo LB, Ramírez-Jarquín UN, Lazo-Gómez R, Tapia R. Trophic factors as modulators of motor neuron physiology and survival: implications for ALS therapy. *Front Cell Neurosci.* 2014;8:61.
31. Tsui CC, Shankland SJ, Pierchala BA. Glial cell line-derived neurotrophic factor and its receptor ret is a novel ligand-receptor complex critical for survival response during podocyte injury. *J Am Soc Nephrol.* 2006;17: 1543–52.
32. Orth SR, Ritz E, Suter-Crazzolara C. Glial cell line-derived neurotrophic factor (GDNF) is expressed in the human kidney and is a growth factor for human mesangial cells. *Nephrol Dial Transplant.* 2000;15(5):589-95.
33. Shi H, Patschan D, Dietz GP, Bähr M, Plotkin M, Goligorsky MS. Glial cell linederived neurotrophic growth factor increases motility and survival of cultured mesenchymal stem cells and ameliorates acute kidney injury. *Am J Physiol. Renal Physiol.* 2008;294(1):F229-35.
34. Steinkamp M, Gundel H, Schulte N, Spaniol U, Pflueger C, Zizer E, *et al.* GDNF protects enteric glia from apoptosis: evidence for an autocrine loop. *BMC Gastroenterology.* 2012;12:16.
35. Komori T. Regulation of osteoblast differentiation by Runx2. *Adv Exp Med Biol.* 2010; 658:43-49.
36. Jiahai Xu, Zhanghua Li, Yudong Hou, Weijun Fang. Potential mechanisms underluing the Runx2 induced osteogenesis of bone marrow mesenchymal stem cells. *Am J Transl Res.* 2015;7:2527-2535.
37. Kirkham GR, Cartmell SH. Genes and proteins involved in the regulation of osteogenesis. In: Ashammakhi N, Reis R, Chiellini E, eds. *Topics in tissue engineering.* 2007;1–22.

38. Wesson JA, Johnson RJ, Mazzali M, Beshensky AM, Stietz S, Giachelli C, *et al.* Osteopontin is a critical inhibitor of calcium oxalate crystal formation and retention in renal tubules. *J Am Soc Nephrol.* 2003;14:139–147.
39. McKe MD, Nanci A, Khan SR. Ultrastructural immunodetection of osteopontin and osteocalcin as major matrix components of renal calculi. *J Bone Miner Res.* 1995;10:1913–1929.
40. Hoyer JR, Asplin JR, Otvos L. Phosphorylated osteopontin peptides suppress crystallization by inhibiting the growth of calcium oxalate crystals. *Kidney Int.* 2001;60: 77–82.
41. Qi H, Aguiar DJ, Williams SM, La Pean A, Pan W, Verfaillie CM, *et al.* Identification of genes responsible for osteoblast differentiation from human mesodermal progenitor cells. *Proc Natl Acad Sci USA.* 2003;100:3305–3310.
42. Koopman G, Reutelingsperger CP, Kuijten GA, Keehnen RM, Pals ST, van Oers MH. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. *Blood.* 1994;84(5):1415-1420.
43. Sgonc R, Gruber J. Apoptosis detection: an overview. *Exp Gerontol.* 1998;33(6):525-533.
44. Trichonas G, Murakami Y, Thanos A, Morizane Y, Kayama M, Debouck CM, *et al.* Receptor interacting protein kinases mediate retinal detachment-induced photoreceptor necrosis and compensate for inhibition of apoptosis. *Proc Natl Acad Sci U S A.* 2010;107: 21695–21700.
45. Grasl-Kraupp B, Ruttkay-Nedecky B, Koudelka H, Bukowska K, Bursch W, Schulte-Hermann R. In situ detection of fragmented DNA (TUNEL assay) fails to discriminate among apoptosis, necrosis, and autolytic cell death: a cautionary note. *Hepatology.* 1995;21: 1465–1468.

46. Gross A, McDonnell JM, Korsmeyer SJ. BCL-2 family members and the mitochondria in apoptosis. *Genes Dev.* 1999;13(15):1899-1911
47. Festjens N, van Gurp M, van Loo G, Saelens X, Vandenabeele P. Bcl-2 family members as sentinels of cellular integrity and role of mitochondrial intermembrane space proteins in apoptotic cell death. *Acta Haematol.* 2004;111(1-2):7-27.
48. Mune S, Shibata M, Hatamura I, Saji F, Okada T, Maeda Y, *et al.* Mechanism of phosphate-induced calcification in rat aortic tissue culture: possible involvement of Pit-1 and apoptosis. *Clin Exp Nephrol.* 2009;13(6):571-577
49. Fujita H, Yamamoto M, Ogino T, Kobuchi H, Ohmoto N, Aoyama E, *et al.* Necrotic and apoptotic cells serve as nuclei for calcification on osteoblastic differentiation of human mesenchymal stem cells in vitro . *Cell Biochem Funct.* 2014;32(1):77-86
50. Bröker LE, Kruyt FA, Giaccone G. Cell death independent of caspases: a review. *Clin Cancer Res.* 2005;11(9):3155-3162.
51. Lockshin RA, Zakeri Z. Caspase-independent cell death? *Oncogene* 2004;23:2766-2773.
52. Lee C Y, Baehrecke E H. Steroid regulation of autophagic programmed cell death during development. *Development.* 2001;128:1443–1455.
53. Sperandio S, de Belle I, Bredesen D E. An alternative, nonapoptotic form of programmed cell death. *Proc Natl Acad Sci USA.* 2000;97:14376–14381.
54. Turmaine M, Raza A, Mahal A, Mangiarini L, Bates GP, Davies SW. Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease. *Proc Natl Acad Sci USA.* 2000;97:8093–8097.
55. Dana E. Christofferson and Junying Yuan. Necroptosis as an alternative form of programmed cell death. *Curr Opin Cell Biol.* 2010;22(2): 263–268.

56. Weinlich R, Oberst A, Beere H M, Green DR. Necroptosis in development, inflammation and disease. *Nature Reviews Molecular Cell Biology*. 2017;18: 127–136.
57. Mulay SR, Desai J, Kumar SV, Eberhard JN, Thomasova D, Romoli S, *et al.* Cytotoxicity of crystals involves RIPK3-MLKL-mediated necroptosis. *Nat Commun*. 2016;7:10274.
58. Gang Liu, Hui Zou, Tongwang Luo, Mengfei Long, Jianchun Bian, Xuezhong Liu, *et al.* Caspase-Dependent and Caspase-Independent Pathways Are Involved in Cadmium-Induced Apoptosis in Primary Rat Proximal Tubular Cell Culture. *PLoS One*. 2016;11(11): e0166823.
59. Al-Lamki RS, Lu W, Manalo P, Wang J, Warren AY, Tolkovsky AM, *et al.* Tubular epithelial cells in renal clear cell carcinoma express high RIPK1/3 and show increased susceptibility to TNF receptor 1-induced necroptosis. *Cell Death Dis*. 2016;30;7(6):e2287.
60. Liang X, Chen Y, Zhang L, Jiang F, Wang W, Ye Z, *et al.* Necroptosis, a novel form of caspase-independent cell death, contributes to renal epithelial cell damage in an ATP-depleted renal ischemia model. *Mol Med Rep*. 2014;10(2):719-724.
61. Zhu Y, Cui H, Xia Y, Gan H. RIPK3-Mediated Necroptosis and Apoptosis Contributes to Renal Tubular Cell Progressive Loss and Chronic Kidney Disease Progression in Rats. *PLoS One*. 2016;11(6):e0156729.
62. Martin-Sanchez D, Poveda J, Fontecha-Barriuso M, Ruiz-Andres O, Sanchez-Niño MD, Ruiz-Ortega M, *et al.* Targeting of regulated necrosis in kidney disease. *Nefrologia*. 2017; <http://dx.doi.org/10.1016/j.nefro.2017.04.004>.
63. Yu LY, Jokitalo E, Sun YF, Mehlen P, Lindholm D, Saarma M, *et al.* GDNF-deprived sympathetic neurons die via a novel nonmitochondrial pathway. *The Journal of Cell Biology*. 2003;987–997

64. Yu LY, Saarma M, Arumäe U.. Death receptors and caspases but not mitochondria are activated in the GDNF- or BDNF-deprived dopaminergic neurons. *J Neurosci.* 2008;28(30):7467–7475
65. Oppenheim RW, Flavell RA, Vinsant S, Prevette D, Kuan CY, Rakic P. Programmed cell death of developing mammalian neurons after genetic deletion of caspases. *J Neurosci.* 2001;21(13):4752-4760.
66. Yaginuma H, Shiraiwa N, Shimada T, Nishiyama K, Hong J, Wang S, *et al.* Caspase activity is involved in, but is dispensable for, early motoneuron death in the chick embryo cervical spinal cord. *Mol Cell Neurosci.* 2001;18(2):168-182.
67. Zaidi AU, D'Sa-Eipper C, Brenner J, Kuida K, Zheng TS, Flavell RA, *et al.* Bcl-X(L)-caspase-9 interactions in the developing nervous system: evidence for multiple death pathways. *J Neurosci.* 2001;21(1):169-175.
68. Marsden VS, O'Connor L, O'Reilly LA, Silke J, Metcalf D, Ekert PG, *et al.* Apoptosis initiated by Bcl-2-regulated caspase activation independently of the cytochrome c/Apaf-1/caspase-9 apoptosome. *Nature.* 2002;419(6907):634-637.
69. Unal-Cevik I, Kiliç M, Can A, Gürsoy-Ozdemir Y, Dalkara T. Apoptotic and necrotic death mechanisms are concomitantly activated in the same cell after cerebral ischemia. *Stroke.* 2004;35(9):2189-2194.
70. Bursch W. The autophagosomal-lysosomal compartment in programmed cell death. *Cell Death Differ.* 2001;8(6):569-581.
71. Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. *Endocr Rev.* 2000;2:115-137.

72. Nørsgaard H, Clark BF, Rattan SI. Distinction between differentiation and senescence and the absence of increased apoptosis in human keratinocytes undergoing cellular aging *in vitro*. *Exp Gerontol*. 1996;31:563-570.
73. Adamova E, Janeckova E, Kleparnik K, Matalova E. Caspases and osteogenic markers-*in vitro* screening of inhibition impact. *In Vitro Cell Dev Biol Anim*. 2016;52(2):144-148.

TABLES

Target	Clone	Host	Manufacturer	Code	dilution
Cleaved Caspase-3 (Asp175)	5A1E	rabbit	Cell Signaling Technology	CST-9664	1:1,000
Cleaved Caspase-9 (Asp330)	D2D4	rabbit	Cell Signaling Technology	CST-7237	1:1,000
Cleaved Caspase-9 (Asp315)	-	rabbit	Cell Signaling Technology	CST-9505	1:1,000
Cleaved PARP (Asp214)	D64E10	rabbit	Cell Signaling Technology	CST-5625	1:1,000
Runx2/CBFA1	-	rabbit	Novus Biologicals	NBP1-77461	1:50
β -Tubulin	H235	rabbit	Santa Cruz Biotechnology	sc-9104	1:50

Table 1. Primary antibodies and dilutions used for in-cell Western analyses.

<i>PRIMERS</i>	<i>NUCLEOTIDE SEQUENCE</i>	<i>T annealing (*C)</i>	<i>NCBI reference sequence</i>	<i>Efficiency (%)</i>
GAPDH Fw GAPDH Rev	GAAGGTGAAGGTCGGAGT TGGCAACAATATCCACTTTACCA	60	NM_17851.1	99.0
HPRT1 Fw HPRT1 Rev	CCTGGCGTCGTCATTAGTGA TCTCGAGCAAGACGTTTCAGT	60	NM_000194.2	97.8
Osteonectin Fw Osteonectin Rev	CCTGGATCTTCTTTCTCCTTTGC ATCAGGCAGGGCTTCTTGCT	60	NM_001309443.1	97.9
Osteopontin Fw Osteopontin Rev	CGAGACCTGACATCCAGTACC GATGGCCTTGTATGCACCATTC	62	NM_001251830.1	96.2
Runx2 Fw Runx2 Rev	CATTCAGATGATGACACTGCC GGATGAAATGCTTGGGAACTG	62	NM_001024630.3	95.2
BAX Fw BAX Rev	GCCGTGGACACAGACTCC AAGTAGAAAAGGGCGAAACC	60	NM_001291428.1	91.2
BCL2 Fw BCL2 Rev	TCATGTGTGTGGAGAGCGTCAA CAGCCAGGAGAAATCAAACAGAGG	60	NM_000633.2	88.9
GDNF Fw GDNF Rev	GGCTATGAAACCAAGGAGGAACTG TCCACCACCCTGTTGCTGTA	64	NM_000514	98.7

Table 2. Primer sequences used in qRT-PCR analyses.

FIGURES and LEGENDS




Figure 1. GDNF knock-down in an HK-2 cell line. (A) GDNF protein detected using immunocytochemistry in wild-type (WT), negative control and silenced (shRNA 4E) cells (Diaplan light microscope (Leitz), magnification 400X). GDNF immunostaining with a polyclonal anti-GDNF antibody revealed a lower signal in the shRNA 4E than in either of controls (WT and Negative Control cells). Light microscope images are representative of the results of two independent experiments. Bar = 25 µm. (B). Changes in *GDNF* gene expression as determined by qRT-PCR ($\Delta\Delta C_t$ method) in WT, negative control and shRNA 4E cells. (C) Changes in GDNF protein expression as determined by morphometric analysis. The results are presented as the mean \pm SD of two independent experiments performed in triplicate. Statistically significant differences between the shRNA 4E and the WT (* $p < 0.005$) and Negative Control (** $p < 0.05$) cells were analyzed using ANOVA with a between-within design and Bonferroni's correction.






Figure 2. Phase-contrast inverted microscope images of silenced cells (shRNA 4E) grown in DMEM/F12 supplemented with 10% HI-FBS or NH OsteoDiff medium. shRNA 4E cells grown in osteogenic medium exhibited multilayer growth with cells retracting from some areas and grouping into multicellular aggregates or nodules with abundant dense deposits. The images (acquired with Hund Wetzlar, Wilovert, magnification 200X) are representative of two independent experiments. Bar = 100 μ m.



A



B

Figure 3. Calcium detection in HK-2 cells cultured in either DMEM/F12 supplemented with 10% HI-FBS or NH OsteoDiff medium. (A) Light microscope images (Diaplan light microscope (Leitz), magnification 100-200X) of von Kossa staining reveal calcium deposits in some cells and nodules in the Negative Control and silenced (shRNA 4E) cells grown in osteogenic medium for 15 days. No calcium deposition was seen in control or silenced cells cultured under standard conditions (DMEM/F12 supplemented with 10% HI-FBS). Low magnification images showed much more abundant dark deposits in the silenced than in the control cells. The images are representative of two independent experiments. Bars = 100 left μm and 50 right μm . **(B)** Quantitative analysis of von Kossa staining with morphometric analyses on days 5 and 15. Statistically significant differences emerged between the shRNA

4E cells and the WT and negative control cells at 5 (*p<0.05) and 15 days (**p<0.005 shRNA 4E vs WT and § p<0.01 vs Negative Control) using a non-parametric test (Mann-Whitney U test) and Primer software (McGraw-Hill).




Figure 4. ESEM analysis of HK-2 cells cultured in DMEM/F12 supplemented with 10% HI-FBS or NH OsteoDiff medium. (A) In silenced cells, ESEM images and spectra confirmed the presence of calcium (Ca) and phosphate (P) in the nodules on day 15 (green arrow). No calcium-phosphate (Ca_2PO_4) deposits were seen in silenced cells cultured under standard conditions. The images are representative of two independent experiments. Bars = 100 μm left, 50 μm right. (B) Quantitative analysis of calcium and phosphate levels in WT, negative control and shRNA 4E cells grown in NH OsteoDiff medium for 15 days. Bar = 500

µm. Statistically significant differences emerged using a non-parametric test (Mann-Whitney U test), and Primer software (McGraw-Hill) (** $p < 0.005$ shRNA vs Negative Control and WT).




Figure 5. Osteogenic-like process in wild-type (WT), negative control and silenced (shRNA 4E) cells grown in osteogenic NH OsteoDiff medium. (A) left: expression of

Runx2 gene by qRT-PCR ($\Delta\Delta C_t$ method); right: expression of Runx2 protein by ICW Fluorescence quantification at 800 nm normalized to the β -tubulin signal. (* $p < 0.05$; ** $p < 0.005$ shRNA vs Negative Control and WT). **(B)** Expression of osteogenesis-related genes as determined by qRT-PCR ($\Delta\Delta C_t$ method). Results are expressed as the ratio of nRQ osteonectin (ON) to nRQ osteopontin (OP) (§ $p < 0.01$, shRNA 4E vs WT; * $p < 0.05$, shRNA 4E vs WT; ** $p < 0.005$, shRNA 4E vs Negative Control). **(C)** ALP staining quantification by morphometric analysis of light microscope images (Leica DMIL LED, magnification 400X) (** $p < 0.005$ shRNA vs Negative Control and WT). Alkaline phosphatase appears as an intense blue/purple stain in the cells (arrows). The images are representative of two independent experiments. Bar = 10 μm .

Results are presented as the mean \pm SD of two independent experiments performed in triplicate. Statistically significant differences emerged using ANOVA with a between-within design and Bonferroni's correction.




Figure 6. Cell proliferation and viability. Results of methyl blue assay (based on optical density) of wild-type (WT), negative control and silenced (shRNA 4E) cell growth in standard (DMEM/F12 supplemented with 10% HI-FBS) and osteogenic (NH OsteoDiff) conditions. Data are presented as the mean \pm SD of three independent experiments. Statistically significant differences emerged between the shRNA 4E and the wild-type and Negative Control cells (** $p < 0.005$) using ANOVA with a between-within design and Bonferroni's correction.




Figure 7. Double staining with annexin V and PI in wild-type (WT), negative control and silenced (shRNA 4E) cells grown in osteogenic (NH OsteoDiff) medium for 5 and 15 days. (A) Percentages of dead and live cells. (B) Cell population (necrosis, early and late apoptosis) involved in the death process. Results are presented as the mean \pm SD of two independent experiments performed in triplicate. Statistically significant differences emerged using ANOVA with a between-within design and Bonferroni's correction (* $p < 0.05$ shRNA 4E vs Negative Control and WT).




Figure 8. Immunofluorescence images of TUNEL-stained apoptotic nuclei (green staining) in negative control and silenced (shRNA 4E) cells grown in NH OsteoDiff medium for 15 days. The images (acquired using a DMI600CS-TCS SP8 fluorescence microscope) are representative of two independent experiments. **A:** Bright field; **B:** FITC; **C:** Merge. Bars = 50 μm and 25 μm. **(D)** Quantitative analysis of TUNEL staining using morphometric analysis. Statistically significant differences emerged between the shRNA 4E cells and Negative Control cells using with a non-parametric test (Mann-Whitney U test) and Primer software (McGraw-Hill) (** p<0.005).




Figure 9. Expression of apoptosis-related genes in wild-type (WT), negative control and silenced (shRNA 4E) cells grown in NH OsteoDiff medium. Changes in *BCL2* and *BAX* mRNA levels measured using qRT-PCR ($\Delta\Delta C_t$). Results are presented as the mean \pm SD of two independent experiments performed in triplicate. Statistically significant differences were calculated using ANOVA with a between-within design and Bonferroni's correction (* $p < 0.05$; ** $p < 0.005$ shRNA vs Negative Control and WT).




Figure 10. Caspase activation in wild-type (WT), negative control and silenced (shRNA 4E) cells grown in NH OsteoDiff medium. (A) Fluorescence quantified at 800 nm and normalized to the β -tubulin signal. Results are presented as the mean \pm SD of two independent experiments performed in triplicate. Statistically significant differences emerged using ANOVA with a between-within design and Bonferroni's correction (* p <0.05; \S p <0.005 shRNA vs Negative Control and WT). (B) Representative image acquired at a wavelength of 800 nm.